Benign prostatic hyperplasia: Antecedents and natural history

Epidemiologic Reviews

Volumn 14, Issue 1, 1992, Pages 131-153

  Guess, Harry A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYPREGNENOLONE; ALPHA ADRENERGIC RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; BASIC FIBROBLAST GROWTH FACTOR; ESTROGEN; GROWTH FACTOR; PRASTERONE; TESTOSTERONE;

ALCOHOL LIVER CIRRHOSIS; BLADDER DISEASE; BLADDER NECK STENOSIS; CIGARETTE SMOKING; DIABETES MELLITUS; DISEASE COURSE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; NONHUMAN; ORGAN SIZE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RACE DIFFERENCE; REVIEW; SEXUAL BEHAVIOR; VASECTOMY;

ADULT; AGED; ESTROGENS; GROWTH SUBSTANCES; HUMAN; MALE; MIDDLE AGE; PREVALENCE; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ADRENERGIC; RISK FACTORS; STANOLONE; TESTOSTERONE;

EID: 0027087205     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a036083     Document Type: Article

References (186)

1. Lauridsen L. From the history of prostatic hyper¬trophy. A medico-historical investigation of its pathology and palliative surgical treatment up to the beginning of the 20th century. Dan Med Bull 1969;16:77-82.
2. National hospital discharge data tapes. Hyatts- ville, MD: National Center for Health Statistics, 1987.
3. National ambulatory medical care survey. Hyatts- ville, MD: National Center for Health Statistics, 1985.
4. Glynn RJ, Campion EW, Bouchard GR, et al. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985;121:78-90.
5. Barry MJ, Beckley S, Boyle P, et al. Importance of understanding the epidemiology and natural history of BPH. In: Cockett ATK, Aso Y, Chatelain C, et al. eds. Proceedings of the inter¬national consultation on benign prostatic hyper-plasia (BPH). Geneva, Switzerland: World Health Organization, 1992:13-21.
6. McNeal JE. The anatomic heterogeneity of the prostate. Prog Clin Biol Res 1980;37:149-60.
7. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12:619-33.
8. McNeal JE. Origin and development of carci¬noma in the prostate. Cancer 1969;23:24-34.
9. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968;49: 347-57.
10. McNeal JE. Origin and evolution of benign pros¬tatic enlargement. Invest Urol 1978;15:340-5.
11. Hinman F Jr. Capsular influence on benign pros¬tatic hyperplasia. Urology 1986;28:347-50.
12. Walsh PC. Benign prostatic hyperplasia. In: Walsh, PC, Retik AB, Stamey TA, et al., eds. Campbell’s urology. 6th edition. Philadelphia, PA: WB Saunders, 1992:1009-25.
13. McNeal J. Pathology of benign prostatic hyperpla¬sia. Insight into etiology. Urol Clin North Am 1990;17:477-86.
14. Walsh PC. Benign prostatic hyperplasia. In: Walsh PC, Gittes RF, Perlmutter AD, et al., eds. Campbell’s urology. 5th edition. Philadelphia, PA: WB Saunders, 1986:1248-65.
15. Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980;68:745-56.
16. Yokoyama M, Seki N, Tamai M, et al. Benign prostatic hyperplasia in a patient castrated in his youth. J Urol 1989;142:134-5.
17. Scott WW. What makes the prostate grow? J Urol 1953;70:477-88.
18. Marinello MJ, Montes M, Farnsworth WE, et al. Benign prostatic hyperplasia in an XX man. Urol¬ogy 1979;13:640-5.
19. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing-hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987;317:599-604.
20. Wilson JD. The intranuclear metabolism of tes¬tosterone in the accessory organs of reproduction. Recent Prog Horm Res 1970;26:309-36.
21. Wilbert DM, Griffin JE, Wilson JD. Characteriza¬tion of the cytosol androgen receptor of the hu¬man prostate. J Clin Endocrinol Metab 1983;56: 113-20.
22. Walsh PC, Hutchins GM, Ewing LL. Tissue con¬tent of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 1983;72:1772-7.
23. Barrack ER, Bujnovszky P, Walsh PC. Subcellular distribution of androgen receptors in human nor¬mal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res 1983;43:1107-16.
24. Wilson JD, Gloyna RE, Siiteri PK. Androgen metabolism in the hypertrophic prostate. J Steroid Biochem Mol Biol 1975;6:443-5.
25. Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976;57:1093-7.
26. Stoner E, The Finasteride Study Group. The clinical effects of a 5-a-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 1992; 147:1298-302.
27. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphro¬ditism. Science 1974;186:1213-15.
28. Imperato-McGinley J. 5-reductase deficiency in man. In: Bresciani F, ed. Hormones and cancer 2. Proceedings of the second international congress on hormones and cancer. Progress in cancer re¬search and therapy. New York: Raven Press, 1984: 491-5.
29. Andersson S, Berman DM, Jenkins EP, et al. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354: 159-61.
30. Ekman P, Barrack ER, Greene GL, et al. Estrogen receptors in human prostate: evidence for multiple binding sites. J Clin Endocrinol Metab 1983;57: 166-76.
31. Hulka BS, Hammond JE, DiFerdinando G, et al. Serum hormone levels among patients with pros¬tatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate 1987;11:171-82.
32. Partin AW, Oesterling JE, Epstein JI. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405-9.
33. Brochu M, Belanger A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 1987;11:33-40.
34. Harper ME, Pike A, Peeling WB, et al. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974;60:117-25.
35. Kadar T, Ben-David M, Pontes JE, et al. Prolactin and luteinizing hormone-releasing hormone re¬ceptors in human benign prostatic hyperplasia and prostate cancer. Prostate 1988;12:299-307.
36. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule, and bladder neck. Br J Urol 1975;47: 193-202.
37. Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17:641-9.
38. Stimson JB, Fihn SD. Benign prostatic hyperplasia and its treatment. J Gen Intern Med 1990;5: 153-65.
39. Lepor H, Baumann M, Shapiro E. The stereospe- cificity of LY253352 for alpha 1-adrenoceptor binding sites in the brain and prostate. Br J Phar¬macol 1988;95:139-44.
40. Lepor H. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hy¬perplasia. Urol Clin North Am 1990;17:651-9.
41. Jacobs SC, Pikna D, Lawsonn RK. Prostatic osteoblastic factors. Invest Urol 1979;17:195-8.
42. Nishi N, Matuo Y, Muguruma Y, et al. A human prostatic growth factor (hPGF): partial purifica¬tion and characterization. Biochem Biophys Res Commun 1985;132:1103-9.
43. Nishi N, Matuo Y, Kunitomi K, et al. Compara¬tive analysis of growth factors in normal and pathologic human prostates. Prostate 1988;13: 39-48.
44. Lawson RK. Benign prostatic hyperplasia and growth factors. Urologe 1990;29:5-7.
45. Morrison AS. Prostatic hypertrophy in greater Boston. J Chronic Dis 1978;31:357-62.
46. Epstein RS, Lydick E, deLabry L, et al. Age- related differences in risk factors for prostatec¬tomy for benign prostatic hyperplasia: the VA Normative Aging Study. Urology 1991;38 (1 suppl):9-12.
47. Sidney S, Quesenberry C Jr, Sadler MC, et al. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 1991;38 (1 suppl):13-19.
48. Morrison AS. Risk factors for surgery for pros¬tatic hypertrophy. Am J Epidemiol 1992; 135: 974-80.
49. Dai WS, Gutai JP, Kuller LH, et al. Cigarette smoking and serum sex hormones in men. Am J Epidemiol 1988;128:796-805.
50. Meikle AW, Liu XH, Taylor GN, et al. Nicotine and cotinine effects on 3 alpha hydroxysteroid dehydrogenase in canine prostate. Life Sei 1988; 43:1845-50.
51. Eldrup E, Lindholm J, Winkel P. Plasma sex hormones and ischemic heart disease. Clin Biochem 1987;20:105-12.
52. Gordon GG, Altman K, Southren AL, et al. Effect of alcohol (ethanol) administration on sex¬hormone metabolism in normal men. N Engl J Med 1976;295:793-7.
53. Nomura AMY, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991, 13: 200-27.
54. Chopra IJ, Tulchinsky D, Greenway FL. Estrogen-androgen imbalance in hepatic cirrhosis. Ann Intern Med 1973;79:198-203.
55. Anderson KE, Kappas A. Hormones and liver function. In: Schiff L, Schiff ER, eds. Diseases of the liver. Philadelphia, PA: JB Lippincott, 1982: 167-236.
56. Boyle P, McGinn R, Maisonneuve P, et al. Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol 1991; 20 (suppl 1):3-10.
57. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990;17:495-507.
58. Bennett HS, Baggenstoss AH, Butt HR. The testis, breast, and prostate of men who die of cirrhosis of the liver. Am J Clin Path 1950;20:814-28.
59. Frea B, Annoscia S, Stanta G, et al. Correlation between liver cirrhosis and benign prostatic hyperplasia: a morphological study. Urol Res 1987; 15:311-14.
60. Robson MC. Cirrhosis and prostatic neoplasms. Geriatrics 1966;21:150-4.
61. Stumpf HH, Wilens SL. Inhibitory effects of portal cirrhosis of liver on prostatic enlargement. Arch Intern Med 1953;91:304-9.
62. Wu SD. Anatomic changes in the prostate of patients with cirrhosis of the liver. Arch Pathol 1942;34:735-41.
63. Moore RA. Benign hypertrophy of the prostate— a morphological study. J Urol 1943;50:680-710.
64. Bourke JB, Griffin JP. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 1966;38:18-23.
65. Marberger H. Causes and consequences of bladder neck obstruction. In: Marberger H, ed. Prostatic disease: American European symposium on pros¬tatic disease, Vienna, Austria, November 3-5, 1975. New York: Liss, 1976:31-48.
66. Jones DA, George NJR, O’Reilly PH, et al. Reversible hypertension associated with unrecog¬nized high-pressure chronic retention of urine. Lancet 1987;1:1052-4.
67. Ghose RR, Harindra V. Unrecognised high pressure chronic retention of urine presenting with systemic arterial hypertension. BMJ 1989;298: 1626-8.
68. Bourke JB, Griffin JP. Diabetes mellitus in patients with benign prostatic hyperplasia. Br Med J 1968;4:492-3.
69. Roberts HJ. The role of diabetogenic hyperinsu- linism in the pathogenesis of prostatic hyperplasia and malignancy. J Am Geriatr Soc 1966; 14: 795-825.
70. Jakobsen H, Torp PS, Juul N, et al. The longterm influence of vasectomy on prostatic volume and morphology in man. Prostate 1988;13:57-67.
71. Sidney S. Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy. J Urol 1987;138:795-7.
72. Araki H, Watanabe H, Mishina T, et al. High-risk group for benign prostatic hypertrophy. Prostate 1983;4:253-64.
73. Steele R, Lees REM, Kraus AS, et al. Sexual factors in the epidemiology of cancer of the pros¬tate. J Chronic Dis 1971;24:29-37.
74. Ekman P. BPH epidemiology and risk factors. Prostate Suppl 1989;2:23-31.
75. Rodman WL. The influence of race, sex, and age in surgical affections. In: Keen WW, ed. Surgery, its principles and practice. 4th edition. Philadel¬phia, PA: WB Saunders, 1908:1139-60.
76. Walker KM. Nature and cause of the old-age enlargement of the prostate. Br Med J 1922;1: 297-301.
77. Randall A. Surgical pathology of prostatic obstructions. Baltimore, MD: Williams & Wilkins, 1931:11-16.
78. D’Aunoy R, Schenken JR, Bums EL. The relative incidence of hyperplasia of the prostate in the white and colored races in Louisiana. South Med J 1939;32:47-52.
79. Derbes VD P, Leche SM, Hooker CW. The incidence of benign prostatic hypertrophy among the whites and Negroes in New Orleans. J Urol 1937; 38:383-8.
80. Kambal A. Prostatic obstruction in Sudan. Br J Urol 1977;49:139-41.
81. Movsas S. Prostatic obstruction in the African and Asiatic. Br J Surg 1966;53:538-43.
82. Houston W. The Bantu prostate: a study of pros¬tatic disease in central Africa. J Urol 1968;99: 316-20.
83. Lissoos I. Simple prostatic hyperplasia in the Bantu. S Afr Med J 1973;47:389-91.
84. Pieterse HF. Some aspects of urological disease among the indigenous peoples of South West Af¬rica. III. Prostatic enlargement and carcinoma of the penis. S Afr Med J 1973;47:2377-9.
85. Amaku EO, Da Rocha-Afodu T, Elebute EA. Prostatic obstruction in Nigerians. West Afr Med J Niger Pract 1971;20:189-94.
86. Sidney S, Quesenberry CP Jr, Sadler MC, et al. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. Am J Epidemiol 1991;134:825-9.
87. Assumpcao C. Some urinary tract disease in Australian aboriginal inpatients in 1980. Aust N Z J Med 1988;18:17-20.
88. Barss PG. Prostatic disease in rural Melanesians. PNG Med J 1985;28:279-82.
89. Stitnimankam T, Thakemgpol K, Tansurat P. Autopsy findings in the aged population of Thai¬land. Arch Pathol 1969;88:181-7.
90. Chang HL, Char GY. Benign hypertrophy of prostate. Chin Med J 1936;50:1707-22.
91. Kato T. Histological study on hyperplasia of the prostate with special reference to histogenesis of nodule. (In Japanese). Jpn J Urol 1967;58: 469-83.
92. Watanabe H, Date S, Ohe H, et al. A survey of 3, 000 examinations by transrectal ultrasonoto- mography. Prostate 1980;1:271-8.
93. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
94. Bostwick DG, Sole Balcells F, Cooner WH, et al. Benign prostatic hyperplasia (BPH) and cancer of the prostate. In: Cockett ATK, Aso Y, Chatelain C, et al., eds. Proceedings of the international consultation on benign prostatic hyperplasia (BPH). Geneva, Switzerland: World Health Or-ganization, 1992:139-59.
95. Rotkin ID. Origins, distribution, and risk of be¬nign prostatic hypertrophy. In: Hinman F Jr, ed. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983:5-9.
96. Birkhoff JD. Natural history of benign prostatic hypertrophy. In: Hinman F Jr, ed. Benign pros¬tatic hypertrophy. New York: Springer-Verlag, 1983:10-21.
97. Stephenson WP, Chute CG, Guess HA, et al. Incidence and outcome of surgery for benign prostatic hyperplasia among residents of Rochester, Minnesota: 1980-87. A population-based study. Urology 1991, 38 (suppl):32-42.
98. Richardson IM. Prostatic hyperplasia and social class. Br J Prev Soc Med 1964;18:157-62.
99. Ashley DJ. Observations on the epidemiology of prostatic hyperplasia in Wales. Br J Urol 1966; 38:567-9.
100. Berry SJ, Coffey DS, Walsh PC, et al. The devel¬opment of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9.
101. Franks LM. Benign nodular hyperplasia of pros¬tate: review. Ann R Coll Surg Engl 1954; 14: 92-106.
102. Swyer GIM. Post-natal growth changes in the human prostate. J Anat 1944;78:130-45.
103. Harbitz TB, Haugen OA. Histology of the prostate in elderly men. A study in an autopsy series. Acta Pathol Microbiol Scand 1972;80:756-68.
104. Pradhan BK, Chandra K. Morphogenesis of nodular hyperplasia—prostate. J Urol 1975; 113: 210-13.
105. Gardner WA Jr, Culberson DE. Atrophy and proliferation in the young adult prostate. J Urol 1987;137:53-6.
106. Tolley DA, English PJ, Grigor KM. Massive benign prostatic hyperplasia. J R Soc Med 1987;80: 777-8.
107. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the com¬munity. Lancet 1991;338:469-71.
108. Jakobsen H, Torp-Pedersen S, Juul N. Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1988;107:26-31.
109. Ohnishi K, Watanabe H, Ohe H. Development of benign prostatic hypertrophy estimated from ul¬trasonic measurements with long-term follow-up. TohokuJExp Med 1987;151:51-6.
110. Watanabe H, Saitoh M, Mishina T, et al. Mass screening program for prostatic diseases with transrectal ultrasonotomography. J Urol 1977; 117:746-8.
111. Meyhoft HH, Haid T. Are doctors able to assess prostatic size? Scand J Urol Nephrol 1978;12: 219-21.
112. Meyhof THH, Ingemann L, Nordling J, et al. Accuracy in preoperative estimation of prostatic size. A comparative evaluation of rectal palpation, intravenous pyelography, urethral closure pres¬sure profile recording and cystourethroscopy. Scand J Urol Nephrol 1981;15:45-51.
113. Hricak H, Jeffrey RB, Dooms GC, et al. Evaluation of prostate size: a comparison of ultrasound and magnetic resonance imaging. Urol Radiol 1987;9:1-8.
114. Graversen PH, Gasser TC, Wasson JH, et al. Controversies about indications for transurethral resection of the prostate. J Urol 1989; 141: 475-81.
115. Jensen KM, Bruskewitz RC, Iversen P, et al. Significance of prostatic weight in prostatism. Urol Int 1983;38:173-8.
116. Donovan JL, Frankel SJ, Abrams P. Prevalence of benign prostatic hypertrophy. (Letter). Lancet 1991;338:1076-7.
117. Claridge M. Analyses of obstructed micturition. Ann R Coll Surg Engl 1966;39:30-53.
118. Abrams PH, Feneley RCL. The significance of symptoms associated with bladder outflow obstruction. Urol Int 1978;33:171-4.
119. Andersen JT, Nordling J, Walter S. Prostatism. I. The correlation between symptoms, cystometric and urodynamic findings. Scand J Urol Nephrol 1979;13:229-36.
120. Epstein RS, Deverka PA, Chute CG, et al. Urinary symptoms and quality of life questions indicative of obstructive benign prostatic hyperplasia: results of a pilot study. Urology 1991;38 (1 suppl):20-6.
121. Frimodt MPC, Jensen KM, Iversen P, et al. Analysis of presenting symptoms in prostatism. J Urol 1984;132:272-6.
122. Arrighi HM, Guess HA, Metter EJ, et al. Symp¬toms and signs of prostatism as risk factors for prostatectomy. Prostate 1990;16:253-61.
123. Simonsen O, Moller-Madsen B, Dorflinger T, et al. The significance of age on symptoms and uro¬dynamic and cystoscopic findings in benign pros¬tatic hypertrophy. Urol Res 1987;15:355-8.
124. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram: I. Development. J Urol 1979; 122: 665-8.
125. Beck AD, Gaudin HJ. The measurement and significance of the urinary flow rate. Aust N Z J Surg 1969;39:99-102.
126. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram: II. Clinical correlation. J Urol 1980; 123:208-10.
127. Drach GW, Layton TN, Binard WJ. Male peak urinary flow rate: relationships to volume voided and age. J Urol 1979;122:210-14.
128. Drach GW, Layton T, Bottaccini MR. A method of adjustment of male peak urinary flow rate for varying age and volume voided. J Urol 1982; 128:960-2.
129. Haylen BT, Ashby D, Sutherst JR, et al. Maximum and average urine flow rates in normal male and female populations—the Liverpool nomo¬grams. Br J Urol 1989;64:30-8.
130. Jorgensen JB, Jensen KM, Bille BNE, et al. Uro- flowmetry in asymptomatic elderly males. Br J Urol 1986;58:390-5.
131. Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979;51:129-34.
132. Abrams PH. Prostatism and prostatectomy: the value of urine flow rate measurement in the pre¬operative assessment for operation. J Urol 1977; 117:70-1.
133. Ball AJ, Smith PJ. Urodynamic factors in relation to outcome of prostatectomy. Urology 1986;28: 256-8.
134. Jensen KM, Jorgensen JB, Mogensen P, et al. Some clinical aspects of uroflowmetry in elderly males. A population survey. Scand J Urol Nephrol 1986;20:93-9.
135. Herbison AE, Fraundorfer MR, Walton JK. Association between symptomatology and uroflow¬metry in benign prostatic hypertrophy. Br J Urol 1988;62:427-30.
136. Abrams PH, Farrar DJ, Turner WRT, et al. The results of prostatectomy: a symptomatic and uro¬dynamic analysis of 152 patients. J Urol 1979; 121:640-2.
137. Turner-Warwick RT, Whiteside CG, Arnold EP, et al. A urodynamic view of static obstruction and the results of prostatectomy. Br J Urol 1973;45: 631-9.
138. Bmskewitz RC, Iversen P, Madsen PO. Value of postvoid residual urine determination in evalua¬tion of prostatism. Urology 1982;20:602-4.
139. Birch NC, Hurst G, Doyle PT. Serial residual volumes in men with prostatic hypertrophy. Br J Urol 1988;62:571-5.
140. Lytton B, Emery JM, Harvard BM. The incidence of benign prostatic obstruction. J Urol 1968;99: 639-45.
141. Arrighi HM, Metter EJ, Guess HA, et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy: The Baltimore Longitudinal Study of Aging. Urology 1991;38 (1 suppl):4-8.
142. Sidney S, Quesenberry CP Jr, Sadler MC, et al. Reoperation and mortality after surgical treat¬ment of benign prostatic hypertrophy in a large prepaid medical care program. Med Care 1992; 30:117-25.
143. Pientka L, Van Loghem J, Hahn E, et al. Comorbidities and perioperative complications among patients with surgically treated benign prostatic hyperplasia. Urology 1991;38 (1 suppl):43-8.
144. Barry MJ, Mulley AG Jr, Fowler FJ, et al. Watch¬ful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients’ preferences. JAMA 1988;259:3010-17.
145. Barnes BA, O’Brien E, Comstock C, et al. Report on variation in rates of utilization of surgical services in the Commonwealth of Massachusetts. JAMA 1985;254:371-5.
146. Wennberg JE, Mulley AG Jr, Hanley D, et al. An assessment of prostatectomy for benign urinary tract obstruction. Geographic variations and the evaluation of medical care outcomes. JAMA 1988;259:3027-30.
147. Wennberg J, Gittelsohn A. Small area variations in health care delivery. Science 1973; 182:1102-8.
148. Wennberg JE. On the status of the Prostate Dis¬ease Assessment Team. Health Serv Res 1990; 25:709-16.
149. Guess HA, Arrighi HM, Metter EJ, et al. Cumu¬lative prevalence of prostatism matches the au¬topsy prevalence of benign prostatic hyperplasia. Prostate 1990;17:241-6.
150. Lytton B. Interracial incidence of benign prostatic hypertrophy. In: Hinman F Jr, ed. Benign pros¬tatic hypertrophy. New York: Springer-Verlag, 1983:22-6.
151. Johnson CL, Chute CG, Panser LA, et al. Natural history of benign prostatic hyperplasia: urinary flow rates in an age stratified randomly sampled group of 2, 113 men. (Abstract). J Urol 1992; 147: 233.
152. Mebust W, Roizo R, Schroeder F, et al. Correla¬tions between pathology, clinical symptoms and the course of the disease. In: Cockett ATK, Aso Y, Chatelain C, et al., eds. Proceedings of the international consultation on benign prostatic hyperplasia (BPH). Geneva, Switzerland: World Health Organization, 1992:53-62.
153. Birkhoff JD, Wiederhorn AR, Hamilton ML, et al. Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 1976;7: 48-52.
154. Ball AJ, Feneley RC, Abrams PH. The natural history of untreated “prostatism”. Br J Urol 1981; 53:613-16.
155. Nohr SB, Jensen BN, Mortensen BB, et al. Hypertrophy of the prostate: “natural history”. Sub¬jective and objective changes during a period of six months. (In Danish). Ugeskr Laeger 1991; 153:1474-7.
156. Craigen AA, Hickling JB, Saunders CR, et al. Natural history of prostatic obstruction. A pro¬spective survey. J R Coll Gen Pract 1969; 18: 226-32.
157. Sacks SH, Aparicio SA, Bevan A, et al. Late renal failure due to prostatic outflow obstruction: a preventable disease. BMJ 1989;298:156-9.
158. Abrams PH, Roylance J, Feneley RC. Excretion urography in the investigation of prostatism. Br J Urol 1976;48:681-4.
159. de Lacey G, Johnson SM, Mee D. Prostatism: how useful is routine imaging of the urinary tract? Br Med J 1988;288:965-7.
160. Kaufman J, Dhakal M, Patel B, et al. Community- acquired acute renal failure. Am J Kidney Dis 1991;17:191-8.
161. Powell PH, Smith PJ, Feneley RC. The identifi¬cation of patients at risk from acute retention. Br J Urol 1980;52:520-2.
162. Anderson JB, Grant JBF. Postoperative retention of urine: a prospective urodynamic study. BMJ 1991;302:894-6.
163. Andersen JT, Vejlsgaard R. The risk of inducing bacteriuria in urodynamic and uroradiological studies of men with prostatism. Scand J Urol Nephrol 1980;14:229-32.
164. Hasner E. Prostatic urinary infection. Acta Chir Scand 1962;Suppl 285:7-40.
165. Grosse H. Frequency, localization and associated disorders in urinary calculi. Analysis of 1671 au¬topsies in urolithiasis. (In German). Z Urol Nephrol 1990;83:469-74.
166. Barry MJ. Medical outcomes research and benign prostatic hyperplasia. Prostate Suppl 1990;3: 61-74.
167. McPherson K, Wennberg JE, Hovind OB, et al. Small-area variations in the use of common sur¬gical procedures: an international comparison of New England, England, and Norway. N Engl J Med 1982;307:1310-14.
168. Wennberg JE, Roos N, Sola L, et al. Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA 1987;257:933-6.
169. Fowler FJ Jr, Wennberg JE, Timothy RP. Symptom status and quality of life following prostatec¬tomy. JAMA 1988;259:3018-22.
170. Roos NP, Wennberg JE, Malenka DJ, et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hy¬perplasia. N Engl J Med 1989;320:1120-4.
171. Andersen TF, Bronnum-Hansen H, Sejr T, et al. Elevated mortality following transurethral resec¬tion of the prostate for benign hypertrophy! But why? Med Care 1990;28:870-81.
172. Concato J, Horwitz RI, Feinstein AR, et al. Prob¬lems of comorbidity in mortality after prostatec¬tomy. JAMA 1992;267:1077-82.
173. Iezzoni LI, Foley SM, Daley J, et al. Comorbidities, complications, and coding bias: does the number of diagnosis codes matter in predicting in-hospital mortality? JAMA 1992, 267: 2297-303.
174. Armenian HK, Lilienfeld AM, Diamond EL, et al. Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet 1974;2:115-17.
175. Greenwald P, Kirmss V, Polan AK, et al. Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst 1974;53:335-40.
176. Franks LM. Benign prostatic hyperplasia. (Letter). Lancet 1974;3:293.
177. Williams RD, Blackard CE. Benign prostatic hyperplasia and cancer of the prostate. (Letter). Lan¬cet 1974;2:1265.
178. Armenian HK. The relationship of benign pros¬tatic hyperplasia to cancer of the prostate—an epidemiologic study. Doctoral thesis. Baltimore, MD: The Johns Hopkins University, 1974.
179. Garnett JE, Oyasu R. Urologie evaluation of atyp¬ical prostatic hyperplasia. Urology 1989;34 (6 suppl):66-9.
180. Helpap B. The biological significance of atypical hyperplasia of the prostate. Virchows Arch [Pathol Anat] 1980;387:307-17.
181. Bostwick DG, Srigley JR. Premalignant lesions. In: Bostwick DG, ed. Pathology of the prostate. New York: Churchill Livingstone, 1990:37-59.
182. Holund B. Latent prostatic cancer in a consecu¬tive autopsy series. Scand J Urol Nephrol 1980; 14:29-35.
183. Billis A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology 1986, 28: 324-9.
184. McNeal JE, Price HM, Redwine EA, et al. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol 1988;139:61-5.
185. Ross RK., Bernstein L, Lobo RA, et al. 5-alpha- reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-9.
186. Mulley AG Jr, Eagle KA. What is inappropriate care? (Editorial). JAMA 1988;260:540-1.